TherapeuticsMD | TXMD - Cash And Equivalent


TherapeuticsMD reported 523K in Cash and Equivalent for its fiscal quarter ending in June of 2024.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 7.46M 985K Sep/2025
CSL USD 2.16B 633M Jun/2025
Grifols EUR 979.78M 334.84M Dec/2024
Novo Nordisk DKK 38.94B 24.15B Mar/2025
Pfizer USD 1.34B 295M Sep/2025
TherapeuticsMD 523K 89K Jun/2024